AU2016336866B2 - Multivalent Fv antibodies - Google Patents

Multivalent Fv antibodies Download PDF

Info

Publication number
AU2016336866B2
AU2016336866B2 AU2016336866A AU2016336866A AU2016336866B2 AU 2016336866 B2 AU2016336866 B2 AU 2016336866B2 AU 2016336866 A AU2016336866 A AU 2016336866A AU 2016336866 A AU2016336866 A AU 2016336866A AU 2016336866 B2 AU2016336866 B2 AU 2016336866B2
Authority
AU
Australia
Prior art keywords
ser
gly
thr
val
tyr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2016336866A
Other languages
English (en)
Other versions
AU2016336866A1 (en
Inventor
Kristina Ellwanger
Ivica FUCEK
Thomas Mueller
Erich Rajkovic
Uwe Reusch
Thorsten Ross
Martin Treder
Michael WEICHEL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Affimed GmbH
Original Assignee
Affimed GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affimed GmbH filed Critical Affimed GmbH
Publication of AU2016336866A1 publication Critical patent/AU2016336866A1/en
Application granted granted Critical
Publication of AU2016336866B2 publication Critical patent/AU2016336866B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2016336866A 2015-10-13 2016-10-13 Multivalent Fv antibodies Ceased AU2016336866B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15189665.1 2015-10-13
EP15189665.1A EP3156417A1 (en) 2015-10-13 2015-10-13 Multivalent fv antibodies
PCT/EP2016/074642 WO2017064221A1 (en) 2015-10-13 2016-10-13 Multivalent fv antibodies

Publications (2)

Publication Number Publication Date
AU2016336866A1 AU2016336866A1 (en) 2018-05-10
AU2016336866B2 true AU2016336866B2 (en) 2023-05-25

Family

ID=54325413

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016336866A Ceased AU2016336866B2 (en) 2015-10-13 2016-10-13 Multivalent Fv antibodies

Country Status (13)

Country Link
US (1) US11572415B2 (enExample)
EP (2) EP3156417A1 (enExample)
JP (1) JP6936497B2 (enExample)
KR (1) KR20180057720A (enExample)
CN (1) CN108473577A (enExample)
AU (1) AU2016336866B2 (enExample)
BR (1) BR112018007445A2 (enExample)
CA (1) CA3001765A1 (enExample)
IL (1) IL258638B2 (enExample)
MX (1) MX2018004547A (enExample)
SG (2) SG11201803083XA (enExample)
WO (1) WO2017064221A1 (enExample)
ZA (1) ZA201802543B (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250091329A (ko) 2015-06-15 2025-06-20 누맙 세러퓨틱스 아게 이종 이량체 다중 특이적 항체 포맷
SG11201912865VA (en) * 2017-06-25 2020-01-30 Systimmune Inc Multi-specific antibodies and methods of making and using thereof
WO2019175368A1 (en) 2018-03-14 2019-09-19 Affimed Gmbh Bispecific egfr/cd16 antigen-binding protein
EP3773621A4 (en) * 2018-03-27 2022-03-23 Systimmune, Inc. GUIDANCE AND NAVIGATION CONTROL PROTEINS AND METHODS FOR THEIR MANUFACTURE AND USE
WO2019199916A1 (en) * 2018-04-13 2019-10-17 Eli Lilly And Company Fab-based trispecific antibodies
EP3774914A2 (en) 2018-04-13 2021-02-17 Affimed GmbH Nk cell engaging antibody fusion constructs
CN112384243A (zh) * 2018-04-17 2021-02-19 英温拉公司 三价三特异性抗体构建体
PL3843757T3 (pl) 2018-08-27 2024-08-05 Affimed Gmbh Kriokonserwowane komórki nk wstępnie obciążone konstruktem przeciwciała
US20220396635A1 (en) * 2019-09-25 2022-12-15 Universität Stuttgart Trivalent binding molecules
CN118580364A (zh) * 2019-11-06 2024-09-03 西雅图免疫公司 制导和导航控制蛋白及其制备和使用方法
CA3160927A1 (en) 2019-12-27 2021-07-01 Affimed Gmbh Method for the production of bispecific fcyriii x cd30 antibody construct
TWI908779B (zh) * 2020-03-17 2025-12-21 美商西雅圖免疫公司 引導及導航控制(gnc)抗體樣蛋白質及製造與使用其之方法
EP4225792A1 (en) 2020-10-08 2023-08-16 Affimed GmbH Trispecific binders
MX2023006573A (es) * 2020-12-03 2023-06-19 Amgen Inc Constructos de inmunoglobulina con multiples dominios de union.
US20250074996A1 (en) * 2021-02-19 2025-03-06 Innovent Biologics (Suzhou) Co., Ltd. ANTI-GPRC5DxBCMAxCD3 TRISPECIFIC ANTIBODY AND USE THEREOF
JP2024529381A (ja) 2021-07-30 2024-08-06 アフィメド ゲーエムベーハー デュプレックスボディ
TW202330594A (zh) 2021-09-29 2023-08-01 美商莫德斯醫療公司 抗原結合多肽、抗原結合多肽複合物及其使用方法
CN114316060B (zh) * 2021-12-15 2023-06-13 北京市肿瘤防治研究所 抗人cd19与cd206双特异性抗体及其制备方法和应用
US20230272069A1 (en) * 2022-02-28 2023-08-31 Institute Of Hematology And Blood Diseases Hospital, Chinese Academy Of Medical Sciences Chimeric Antigen Receptor Targeting CD22 and CD19 and Application thereof
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
EP4719352A1 (en) 2023-05-31 2026-04-08 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025235413A1 (en) * 2024-05-05 2025-11-13 Duke University Compositions targeting cancer antigens and methods of use thereof
WO2026087751A1 (en) 2024-10-24 2026-04-30 Affimed Gmbh Combination of immune cell engager and nk cell products
EP4751731A1 (en) 2024-11-29 2026-06-03 Affimed GmbH Combination of a bispecific antibody construct, an immune checkpoint inhibitor and a taxane
EP4751777A1 (en) 2024-11-29 2026-06-03 Affimed GmbH Combination of a bispecific antibody construct, an immune checkpoint inhibitor and a vegfr-2 inhibitor
EP4751734A1 (en) 2024-11-29 2026-06-03 Affimed GmbH Bispecific antibody construct dosage regimen for treating nsclc

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
ATE387458T1 (de) * 1994-01-07 2008-03-15 Mochida Pharm Co Ltd Fas-antigenbindender ligand
US5989830A (en) * 1995-10-16 1999-11-23 Unilever Patent Holdings Bv Bifunctional or bivalent antibody fragment analogue
AU2001270609A1 (en) * 2000-06-30 2002-01-14 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Heterodimeric fusion proteins
ATE346866T1 (de) * 2001-09-14 2006-12-15 Affimed Therapeutics Ag Multimerische, einzelkettige, tandem-fv- antikörper
PL372144A1 (en) 2001-12-26 2005-07-11 Immunomedics, Inc. Methods of generating multispecific, multivalent agents from v sb h /sb and v sb l /sb domains
US20120237442A1 (en) 2005-04-06 2012-09-20 Ibc Pharmaceuticals, Inc. Design and Construction of Novel Multivalent Antibodies
GB0510790D0 (en) * 2005-05-26 2005-06-29 Syngenta Crop Protection Ag Anti-CD16 binding molecules
WO2008007755A1 (en) * 2006-07-13 2008-01-17 Chugai Seiyaku Kabushiki Kaisha Cell death inducer
EP2014680A1 (en) * 2007-07-10 2009-01-14 Friedrich-Alexander-Universität Erlangen-Nürnberg Recombinant, single-chain, trivalent tri-specific or bi-specific antibody derivatives
GB201003701D0 (en) * 2010-03-05 2010-04-21 Cilian Ag System for the expression of a protein
FR2959416B1 (fr) * 2010-05-03 2012-06-22 Monoclonal Antibodies Therapeutics Mat Biopharma Utilisation d'anticorps anti-cd71 pour la preparation d'un medicament
US20120195900A1 (en) 2010-12-22 2012-08-02 Abbott Laboratories Tri-variable domain binding proteins and uses thereof
TWI622597B (zh) * 2011-03-28 2018-05-01 賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
RU2693078C2 (ru) * 2012-12-03 2019-07-01 Новиммун С.А. Анти-cd47 антитела и способы их применения
EP2938637A2 (en) 2012-12-28 2015-11-04 AbbVie Inc. Multivalent binding protein compositions
WO2014201378A1 (en) * 2013-06-13 2014-12-18 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-pk il -2 and adoptive cell therapy
EP2930188A1 (en) * 2014-04-13 2015-10-14 Affimed Therapeutics AG Trifunctional antigen-binding molecule
KR20250091329A (ko) * 2015-06-15 2025-06-20 누맙 세러퓨틱스 아게 이종 이량체 다중 특이적 항체 포맷

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SCHUBERT, I., et al., 'A single-chain triplebody with specificity for CD19 and CD33 mediates effective lysis of mixed lineage leukemia cells by dual targeting', mAbs. 2011, vol. 3, no. 1, pages 21-30 *

Also Published As

Publication number Publication date
US20190040155A1 (en) 2019-02-07
SG10202004094VA (en) 2020-05-28
SG11201803083XA (en) 2018-05-30
EP3156417A1 (en) 2017-04-19
JP6936497B2 (ja) 2021-09-15
AU2016336866A1 (en) 2018-05-10
KR20180057720A (ko) 2018-05-30
IL258638A (en) 2018-06-28
RU2018126966A (ru) 2020-02-10
US11572415B2 (en) 2023-02-07
BR112018007445A2 (pt) 2019-12-10
JP2018537415A (ja) 2018-12-20
ZA201802543B (en) 2020-01-29
IL258638B (en) 2022-12-01
RU2018126966A3 (enExample) 2020-04-20
CN108473577A (zh) 2018-08-31
IL258638B2 (en) 2023-04-01
CA3001765A1 (en) 2017-04-20
EP3362478A1 (en) 2018-08-22
WO2017064221A1 (en) 2017-04-20
MX2018004547A (es) 2018-11-09

Similar Documents

Publication Publication Date Title
US11572415B2 (en) Multivalent FV antibodies
AU2015249006B2 (en) Trifunctional antigen-binding molecule
US20240294647A1 (en) Uses of nk cell engaging antibody fusion constructs for treatments
US20230390338A1 (en) Antigen binding receptors
CN111527109B (zh) 以抗体Fc区为骨架的融合蛋白二聚体及其应用
CN110382539B (zh) 用于cd16a定向的nk细胞结合的串联双抗体
KR20240033025A (ko) Bcma-지시된 세포 면역요법 조성물 및 방법
US20240174768A1 (en) Bispecific antibodies enhancing cell mediated immune responses
RU2785766C2 (ru) Мультивалентные fv-антитела
RU2785766C9 (ru) Мультивалентные fv-антитела
US20250312452A1 (en) Antibody targeting claudin18.2 and its applications
HK1260025A1 (zh) 多价fv抗体
NZ721138B2 (en) Bispecific t cell activating antigen binding molecules

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired